Compare GOSS & SLRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GOSS | SLRC |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 726.8M | 771.9M |
| IPO Year | 2019 | 2010 |
| Metric | GOSS | SLRC |
|---|---|---|
| Price | $3.45 | $16.08 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 7 |
| Target Price | $8.60 | ★ $16.04 |
| AVG Volume (30 Days) | ★ 2.8M | 253.7K |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | ★ 10.19% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.65 |
| Revenue | $44,051,000.00 | ★ $219,666,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.41 | N/A |
| P/E Ratio | ★ N/A | $9.75 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.71 | $13.64 |
| 52 Week High | $3.60 | $17.94 |
| Indicator | GOSS | SLRC |
|---|---|---|
| Relative Strength Index (RSI) | 64.60 | 67.53 |
| Support Level | $3.25 | $15.97 |
| Resistance Level | $3.45 | $16.14 |
| Average True Range (ATR) | 0.19 | 0.22 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 83.61 | 98.12 |
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. It invests majorly in leveraged middle-market companies in the form of senior secured loans, financing leases and to a lesser extent, unsecured loans and equity securities.